OBJECTIVE Donepezil, an inhibitor of acetylcholinesterase (AChE) targeting the brain, is a common medication for Alzheimer's disease. Interestingly, a recent clinical study found that administration of this agent is associated with lower risk of hip fracture independently of falling, suggesting its direct effect on bone tissues as well. AChE has been reported to be involved in osteoblast functi...

BACKGROUND Treatment of mild cognitive impairment (MCI) with cholinesterase inhibitors may improve symptoms. METHODS In this multicenter, randomized, placebo-controlled trial, subjects with MCI entered a 3-week placebo run-in period followed by 48 weeks of double-blind donepezil (5 mg/day for 6 weeks, then 10 mg/day for 42 weeks) or placebo treatment. Primary efficacy variables included chang...

Donepezil, a member of the acetylcholinesterase inhibitor family, is approved for management of cognitive impairments as well as behavioral complications in patients with neurodegenerative Alzheimer's disease. Generally, donepezil is regarded as a safe medication in patients with Alzheimer's disease although there have been reports of several minor adverse events including gastrointestinal dist...

Donepezil, the most widely used drug for treatment of Alzheimer's disease (AD), is an acetylcholinesterase (AChE) inhibitor and thought to improve cognition by stimulating cholinergic neurotransmission. However, no correlation has yet been established between inhibitory role AChE inhibitors their therapeutic effects when in AD patients. The cleavage pathway amyloid precursor protein (APP) inclu...

buprenorphine is a partial mu agonist and kappa antagonist which is used for the treatment of pain and opioid addiction. a mixture of buprenorphine hydrochloride and naloxone hydrochloride has been approved for the treatment of opioid dependence.in this study a third order derivative spectrophotometric method based on zero-crossing technique has been used for the simultaneous determination of b...

Introduction. Acute renal failure (ARF) develops in 33% of the patients with rhabdomyolysis. The main etiologic factors are alcoholism, trauma, exercise overexertion, and drugs. In this report we present a rare case of ARF secondary to probably donepezil-induced rhabdomyolysis. Case Presentation. An 84-year-old male patient was admitted to the emergency department with a complaint of generalize...

BACKGROUND/AIM Recent data have indicated that the rs1080985 single nucleotide polymorphism (SNP) of the cytochrome P450 (CYP) 2D6 and the common apolipoprotein E (APOE) gene may affect the response to donepezil in patients with Alzheimer's disease (AD). We investigated this association in Chinese patients with mild-to-moderate AD. METHODS In this prospective cohort study, analyses of CYP2D6 ...

The purpose of this paper is to examine whether oxiracetam and aniracetam are more effective than donepezil and tacrine, two drugs currently used to treat Alzheimer’s disease. Past research suggests that oxiracetam and aniracetam are more therapeutically efficacious than donepezil and tacrine in the treatment of Alzheimer’s disease symptoms (i.e., cognitive deterioration, tolerability, and qual...

AIM The aim of this study was to investigate the metabolism and elimination of donepezil HCl in humans, following the administration of a single 5 mg (liquid) oral dose containing a mixture of unlabelled and 14C-labelled donepezil. METHODS This was an open-label, non-randomized study in healthy male volunteers (n = 8). Characterization of donepezil metabolism and elimination was performed by ...

BACKGROUND Treatment of Alzheimer's disease with acetylcholinesterase inhibitors can result in symptomatic benefits, but patients often show variable responses. The objective of this post hoc analysis was to investigate relationships between easily identifiable baseline characteristics/demographics and cognitive response in patients treated with either donepezil 23 mg/d or 10 mg/d and to identi...